Ariad Pharmaceuticals Inc. announced the initiation of a pivotal global Phase 2 trial of AP26113 in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who were previously treated with crizotinib. The ALTA (ALK in Lung Cancer Trial of AP26113) trial is designed to determine the safety and efficacy of AP26113 in refractory NSCLC patients who test positive for the anaplastic lymphoma kinase (ALK+) oncogene.“Preliminary data from more than 120 patients studied thus far in the ongoing Phase 1/2 trial have provided important insights into the safety and efficacy of AP26113 and its profile at different dose levels,” said Frank Haluska, senior vice president of clinical research and development and chief medical officer at Ariad. “We anticipate that the Phase 2 ALTA trial will give us the opportunity to further substantiate these encouraging findings and, importantly, to study two distinct doses of AP26113, which will allow for the potential to optimize its activity in patients with brain metastases.”
Date: March 24, 2014
Source: Ariad
